O objetivo primário é avaliar, em participantes com câncer ovariano seroso de alto grau (high-grade serous ovarian cancer, HGSOC), se a redução em relação à avaliação inicial no DNA tumoral circulante (ctDNA) no ciclo 3 (ΔctDNA) é maior em participantes recebendo MK-4830 + pembrolizumabe em combinação com a terapia padrão de tratamento (SOC) do que … Continued
O objetivo primário é comparar pembrolizumabe mais paclitaxel com ou sem bevacizumabe ao placebo mais paclitaxel com ou sem bevacizumabe em relação à sobrevida livre de progressão (SLP) de acordo com os Critérios de avaliação de resposta em tumores sólidos (Response Evaluation Criteria in Solid Tumors, RECIST) 1.1, conforme avaliado pelo investigador. As hipóteses são … Continued
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that
